Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an α1-adrenoceptor blocker

Shinobu Kato, Mamoru Kusaka, Ryoichi Shiroki, Masanobu Izumitani, Haruyoshi Asano, Takahiro Ooki, Masanori Yanaoka, Kiyotaka Hoshinaga

研究成果: ジャーナルへの寄稿学術論文査読

2 被引用数 (Scopus)

抄録

We examined the effectiveness of supplemental administration of flavoxate hydrochloride in patients with benign prostatic hyperplasia (BPH) whose nocturia was not adequately relieved by an α1-adrenoceptor blocker. Fifty-two patients who had two or more nocturnal micturition after administration of tamsulosin hydrochloride or naftopidil for 4 weeks or more received 400-600 mg of flavoxate hydrochloride in addition to an α1-adrenoceptor blocker for another 8-12 weeks. With supplemental administration of flavoxate hydrochloride, significant improvement was observed in the number of nocturnal micturition, total International Prostate Sympton Score, quality of life score and BPH impact index. No significant change was observed in the voided volume, Qmax, voiding time and residual urine volume. Supplemental administration of flavoxate hydrochloride is therefore effective for the improvement of nocturia and QOL in BPH patients resistant to an α1-adrenoceptor blocker.

本文言語英語
ページ(範囲)173-177
ページ数5
ジャーナルActa Urologica Japonica
54
3
出版ステータス出版済み - 03-2008

All Science Journal Classification (ASJC) codes

  • 医学一般

フィンガープリント

「Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an α1-adrenoceptor blocker」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル